You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Dow
Baxter
Harvard Business School

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Ariad Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Ariad
International Patents:141
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Ariad

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No   Start Trial   Start Trial
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-002 Apr 28, 2017 RX Yes No 9,611,283   Start Trial   Start Trial
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-003 Oct 2, 2017 RX Yes Yes   Start Trial   Start Trial
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No 10,385,078   Start Trial Y Y   Start Trial
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No 8,114,874   Start Trial Y Y   Start Trial
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-003 Oct 2, 2017 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Ariad Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1973545 13C0069 France   Start Trial PRODUCT NAME: PONATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, SOLVATE OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545 2013/059 Ireland   Start Trial PRODUCT NAME: PONATINIB IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
2300013 300990 Netherlands   Start Trial PRODUCT NAME: BRIGATINIB, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1264 20181126
1973545 C300631 Netherlands   Start Trial PRODUCT NAME: PONATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
2300013 122019000046 Germany   Start Trial PRODUCT NAME: BRIGATINIB, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1264 20181122
2300013 PA2019510 Lithuania   Start Trial PRODUCT NAME: BRIGATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1264 20181122
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
Colorcon
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.